|Table of Contents|

Research progress of Notch signaling pathway regulating tumor-associated macrophage differentiation and influencing invasion of NSCLC cells

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 16
Page:
3144-3149
Research Field:
Publishing date:

Info

Title:
Research progress of Notch signaling pathway regulating tumor-associated macrophage differentiation and influencing invasion of NSCLC cells
Author(s):
DAI Can; KONG Yingjun; LIU Hang; ZHANG Na
Department of Respiratory Medicine,the First Affiliated Hospital of Harbin Medical University,Heilongjiang Harbin 150001,China.
Keywords:
Notch; tumor-associated macrophages; non-small cell lung cancer; tumor microenvironment
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2024.16.032
Abstract:
Non-small cell lung cancer (NSCLC) is a common malignant tumor in clinical practice.The invasion and metastasis of cancer cells are the main causes of death in NSCLC patients,and tumor-associated macrophages (TAMs) are closely related to it.TAMs are important component of tumor-infiltrating immune cells and have a tendency to differentiate into M2 phenotype in the tumor microenvironment (TME),which can promote the proliferation,invasion and migration of tumor cells.The differentiation of TAMs is regulated by many cytokines and signaling pathways.Notch signaling pathway is one of them.In this paper,we reviewed the related studies on Notch signaling pathway regulating TAMs differentiation and influencing the invasion of NSCLC cells,so as to provide valuable data for the diagnosis and treatment of NSCLC.

References:

［1］ 中国医师协会肿瘤医师分会,中国医疗保健国际交流促进会肿瘤内科分会.Ⅳ期原发性肺癌中国治疗指南(2023年版)［J］.中国综合临床,2023,39(03):161-190. Chinese Association for Clinical Oncologist,Medical Branch of Chinese International Exchange and Promotion Association for Medical and Healthcare.Clinical practice guideline for stage Ⅳ primary lung cancer in China (2023 edition)［J］.Clinical Medicine of China,2023,39(03):161-190.
［2］ CHEN SS,TANG JQ,LIU F,et al.Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments［J］.Front Immunol,2023,14:1094764.
［3］ HU JJ,ZHANG LL,XIA HR,et al.Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing［J］.Genome Med,2023,15(1):14.
［4］ LI XX,YAN XC,WANG YF,et al.The Notch signaling pathway:a potential target for cancer immunotherapy［J］.J Hematol Oncol,2023,16:45.
［5］ PALAGA T,WOKUEANJINDA P,KUEANJINDA P.Notch signaling in macrophages in the context of cancer immunity［J］.Front Immunol,2018,9:652.
［6］ LEONETTI A,FACCHINETTI F,MINARI R,et al.Notch pathway in small-cell lung cancer:from preclinical evidence to therapeutic challenges［J］.Cell Oncol (Dordr),2019,42(3):261-273.
［7］ MASUKO K,MASARU K.Precision medicine for human cancers with Notch signaling dysregulation (Review)［J］.Int J Mol Med,2020,45(2):279-297.
［8］ MISIOREK JO,PRZYBYSZEWSKA-PODSTAWKA A,KALAFUT J,et al.Context matters:NOTCH signatures and pathway in cancer progression and metastasis［J］.Cells,2021,10(1):94.
［9］ MCLNTYRE B,ASAHHARA T,ALEV C.Overview of basic mechanisms of notch signaling in development and disease［J］.Adv Exp Med Biol,2020,1227:9-27.
［10］ DANAHAY H,PESSOTTI AD,COOTE J,et al.Notch2 is required for inflammatory cytokine-driven goblet cell metaplasia in the lung［J］.Cell Rep,2015,10(2):239-252.
［11］ HASSAN WA,YOSHIDA R,KUDOH S,et al.Evaluation of role of Notch3 signaling pathway in human lung cancer cells［J］.J Cancer Res Clin Oncol,2016,142(5):981-993.
［12］ YONG G,CHENG XY,HAN MF.ZEB1-activated Notch1 promotes circulating tumor cell migration and invasion in lung squamous cell carcinoma［J］.Clin Transl Oncol,2023,25(3):817-829.
［13］ HUANG SX,LI CJ,HUANG JF,et al.LncRNA FEZF1-AS1 promotes non-small lung cancer cell migration and invasion through the up-regulation of NOTCH1 by serving as a sponge of miR-34a［J］.BMC Pulm Med,2020,20(1):110.
［14］ 庄其宏,陈岚兰,卢芳,等.非小细胞肺癌组织中NOTCH1的表达情况及其与患者临床特征和EGFR基因突变状态的关系［J］.癌症进展,2020,18(01):55-57+68. ZHUANG QH,CHEN LL,LU F,et al.Expression of NOTCH1 in non-small cell lung cancer and the relationship with patients' clinical characteristics and EGFR mutations［J］.Oncology Progress,2020,18(01):55-57+68.
［15］HASSAN WA,ITO T.Identifying specific Notch1 target proteins in lung carcinoma cells［J］.Histol Histopathol,2021,36(1):69-76.
［16］黄晓峰,张宁,王亚芳,等.siRNA下调Notch3表达对非小细胞肺癌骨转移能力的影响［J］.现代肿瘤医学,2014,22(11):2534-2538. HUANG XF,ZHANG N,WANG YF,et al.The effect of downregulation Notch3 by siRNA on bone metastasis in non small cell lung cancer［J］.Modern Oncology,2014,22(11):2534-2538.
［17］ PORCHERI C,MITSIADIS TA.Notch in head and neck cancer［J］.Adv Exp Med Biol,2021,1287:81-103.
［18］ MOTOOKA Y,FUJINO K,SATO Y,et al.Pathobiology of Notch2 in lung cancer［J］.Pathology,2017,49(5):486-493.
［19］ SHARIF A,SHAJI A,CHAMMAA M,et al.Notch transduction in non-small cell lung cancer［J］.Int J Mol Sci,2020,21(16):5691.
［20］ PEDROSA AR,TRINGADE A,CARVALHO C,et al.Endothelial Jagged1 promotes solid tumor growth through both pro-angiogenic and angiocrine functions［J］.Oncotarget,2015,6(27):24404-24423.
［21］ ZHAO GL,ZHANG YY,ZHAO ZH,et al.MiR-153 reduces stem cell-like phenotype and tumor growth of lung adenocarcinoma by targeting Jagged1［J］.Stem Cell Res Ther,2020,11(1):170.
［22］ 王捷,张亚楠,张瑜,等.Jagged1对非小细胞肺癌细胞增殖、转移和凋亡的影响及机制研究［J］.河北医药,2020,42(17):2576-2579+2584. WANG J，ZHANG YN，ZHANG Y，et al．Effects of Jagged1 on proliferation，metastasis and apoptosis of non small cell lung cancer cells and its action mechanism［J］.Hebei Medical Journal,2020,42(17):2576-2579+2584.
［23］LIU ZY,WU T,LI Q,et al.Notch signaling components:Diverging prognostic indicators in lung adenocarcinoma［J］.Medicine (Baltimore),2016,95(20):e3715.
［24］ KRISHNAN V,SCHAAR B,TALLAPRAGADA S,et al.Tumor associated macrophages in gynecologic cancers［J］.Gynecol Oncol,2018,149(1):205-213.
［25］ XU L,XIE X,LUO Y.The role of macrophage in regulating tumour microenvironment and the strategies for reprogramming tumour-associated macrophages in antitumour therapy［J］.Eur J Cell Biol,2021,100(2):151153.
［26］ 杨健,徐君南,井明晰,等.ADCC相关免疫细胞预测单克隆抗体抗肿瘤疗效研究进展［J］.中华肿瘤防治杂志,2018,25(01):70-76. YANG J,XU JN,JING MX,et al.Advances of immune cells associated with ADCC predicting the anti-tumor effect of monoclonal antibody［J］.Chinese Journal of Cancer Prevention and Treatment,2018,25(01):70-76.
［27］ ZHAO YS,GUO SP,DENG J,et al.VEGF/VEGFR-targeted therapy and immunotherapy in non-small cell lung cancer:Targeting the tumor microenvironment［J］.Int J Biol Sci,2022,18(9):3845-3858.
［28］ WANG N,WANG S,WANG X,et al.Research trends in pharmacological modulation of tumor-associated macrophages［J］.Clin Transl Med,2021,11(1):e288.
［29］ LI C,XU X,WEI S,et al.Tumor-associated macrophages:potential therapeutic strategies and future prospects in cancer［J］.J Immunother Cancer,2021,9(1):e001341.
［30］ LARIONOVA I,CHERDYNTSEVA N,LIU T,et al.Interaction of tumor-associated macrophages and cancer chemotherapy［J］.Oncoimmunology,2019,8(7):1596004.
［31］ 王皓月,陈建,罗彦波,等.喉癌微环境及代谢特征的研究进展［J］.中国细胞生物学学报,2021,43(02):428-437. WANG HY,CHEN J,LUO YB,et al.Research progresses on tumor microenvironment and metabolic characteristics of laryngeal carcinoma［J］.Chinese Journal of Cell Biology,2021,43(02):428-437.
［32］ ARAMINI B,MASCIALE V,GRISENDI G,et al.Cancer stem cells and macrophages:molecular connections and future perspectives against cancer［J］.Oncotarget,2021,12(3):230-250.
［33］ 袁世洋,徐慧,谢军平.肿瘤微环境内的免疫细胞、PD-1与EGFR-TKIs疗效关系新进展［J］.中国肺癌杂志,2017,20(11):775-780. YUAN SY,XU H,XIE PJ.New progress in the relationship between immune cells,PD-1 in tumor microenvironment and the efficacy of EGFR-TKIs［J］.Chinese Journal of Lung Cancer,2017,20(11):775-780.
［34］ ZHANG H,ZHAO B,ZHAI ZG,et al.Expression and clinical significance of MMP-9 and P53 in lung cancer［J］.Eur Rev Med Pharmacol Sci,2021,25(3):1358-1365.
［35］ SHEN Q,REEDIJK M.Notch signaling and the breast cancer microenvironment［J］.Adv Exp Med Biol,2021,1287:183-200.
［36］ MEURETTE O,MEHLEN P.Notch signaling in the tumor microenvironment［J］.Cancer Cell,2018,34(4):536-548.
［37］ FASOULAKIS Z,DASKALAKIS G,THEODORA M,et al.The relevance of Notch signaling in cancer progression［J］.Adv Exp Med Biol,2021,1287:169-181.
［38］ PALAGA T,WONGCHANA W,KUEANJINDA P.Notch signaling in macrophages in the context of cancer immunity［J］.Front Immunol,2018,9:652.
［39］ ZHAO JL,HUANG F,HE F,et al.Forced activation of Notch in macrophages represses tumor growth by upregulating miR-125a and disabling tumor-associated macrophages［J］.Cancer Res,2016,76(6):1403-1415.
［40］ FRANKLIN RA,LIAO W,SARKAR A,et al.The cellular and molecular origin of tumor-associated macrophages［J］.Science,2014,344(6186):921-925.
［41］ WANG YC,HE F,FENG F,et al.Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses［J］.Cancer Res,2010,70(12):4840-4849.
［42］ PAGIE S,GERARD N,CHARREAU B.Notch signaling triggered via the ligand DLL4 impedes M2 macrophage differentiation and promotes their apoptosis［J］.Cell Commun Signal,2018,16(1):4.
［43］ YIN JZ,SHI XQ,WANG MD,et al.Arsenic trioxide elicits anti-tumor activity by inhibiting polarization of M2-like tumor-associated macrophages via Notch signaling pathway in lung adenocarcinoma［J］.Int Immunopharmacol,2023,117:109899.

Memo

Memo:
-
Last Update: 1900-01-01